Background-Clinical guidelines recommend similar medical therapy for patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation MI (NSTEMI). Methods and Results-Using the Get with the Guidelines-Coronary Artery Disease registry (GWTG-CAD), we analyzed data including 72 352 patients (48 966, NSTEMI; 23 386, STEMI) from 237 US sites between May 1, 2006 and March 21, 2010. Performance and quality measures were compared between NSTEMI and STEMI patients. NSTEMI patients were older and had a higher rate of medical comorbidities compared with STEMI patients, including prior coronary artery disease (38.5% versus 24.7%; P<0.0001), heart failure (17.5% versus 6.2%; P<0.0001), hypertension (70.8% versus 59.1%; P<0.0001) and diabetes mellitus (34.9 versus 23.3%; P<0.0001). Adjusting for confounding variables, STEMI patients were more likely to receive aspirin within 24 hours 98.5% versus 97.1% (adjusted odds ratio [AOR], 1.63; 95% confidence interval [CI], 1.32-2.02), be discharged on aspirin 98.5% versus 97.3% (AOR, 1.33; 95% CI, 1.19-1.49), β-blockers 98.2% versus 96.9% (AOR, 1.48; 95% CI, 1.35-1.63), or lipid-lowering medication for low-density lipoprotein level >100 mg/dL 96.8% versus 91.0% (AOR, 1.85; 95% CI, 1.61-2.13). STEMI patients were also more likely to receive β-blockers within 24 hours of hospital arrival 93.9% versus 90.8% (AOR, 1.57; 95% CI, 1.37-1.79) and the following discharge medications: angiotensin-converting enzyme inhibitors or angiotensin receptor blocking agents 85.3% versus 77.4% (AOR, 1.62; 95% CI, 1.51-1.75), clopidogrel 85.6% versus 67.0% (AOR, 2.42; 95% CI, 2.23-2.61) or lipidlowering medications 94.8% versus 88.0% (AOR, 1.71; 95% CI, 1.56-1.86). Conclusions-Among hospitals participating in GWTG-CAD, adherence with guideline-based medical therapy was high for patients with both STEMI and NSTEMI. Yet, there is still room for further improvement, particularly in the care of NSTEMI patients. (Circ Cardiovasc Qual Outcomes. 2012;5:654-661.) Key Words: acute myocardial infarction ◼ coronary artery disease ◼ myocardial infarction ◼ non-ST-segment elevation acute coronary syndromes ◼ ST-segment elevation myocardial infarction
A lthough different diagnoses, the professional society guideline recommendations for the treatment of acute myocardial infarction (MI) presenting with ST-segment elevation MI (STEMI) and non-ST-segment elevation MI (NSTEMI) with medications are nearly identical. The early use of antiplatelet agents, β-blockers, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blocking (ARB) agents, and statin therapy are mainstays of treatment for both types of infarction. The American College of Cardiology and American Heart Association have published consensus guidelines to educate and promote increased clinician use of these evidence-based therapies. These are summarized in Table  1 . 1, 2 The guidelines for treatment of NSTEMI and STEMI have been updated, and recommendations for performance improvement measures are nearly identical. 3, 4 Despite the similarity in these guidelines for treatment of STEMI and NSTEMI, both data from the United States National Registry of Myocardial Infarction (NRMI) 4 database, collected between 2000 and 2002, and from the French Observatoire sur la Prise en charge hospitalière, l'Evolution à un an et les caractéristiques de patients présentant un infarctus du myocarde avec ou sans onde Q (OPERA) registry, collected from 2002 to 2003, show adherence to guideline-based medical therapy is significantly lower in patients suffering NSTEMI than STEMI. 5, 6 It has also been shown that patients suffering NSTEMI have a higher rate of comorbidities, including a history of previous MI, coronary revascularization or extra cardiac atherosclerotic vascular disease, and may contribute to an overall worse prognosis in this cohort. [5] [6] [7] The presence of these factors makes initiation of guideline-based therapy even more critical. Failure to adhere to evidence-based treatments results in inferior outcomes, including increased mortality in both conditions. 8 Whether differences in the use of guideline-recommended medications in NSTEMI and STEMI care are smaller among hospitals participating in a performance improvement program has not been well studied. To explore this topic, we have examined a large contemporary national dataset, the Get with the Guidelines-Coronary Artery Disease (GWTG-CAD) performance improvement registry, to determine whether adherence to guideline-based therapies differs between patients presenting to the hospital with STEMI versus NSTEMI.
Methods Database
The data in this study were collected from the GWTG-CAD registry. The GWTG-CAD is a large national registry created by the American Heart Association with an aim of assisting hospitals and providers to adhere to guideline-based recommendations. The specific features and goals of the GWTG program have been described previously. 9, 10 Participation in the GWTG-CAD registry is on a voluntary basis and includes a large number of US hospitals. These facilities represent all regions of the country, in both urban and rural settings, and both academic and community-based medical centers. Institutions participating in the GWTG-CAD registry submit clinical information regarding the medical history, hospital care, and outcomes of consecutive patients who are hospitalized for coronary artery disease using an online, interactive case report form and Patient Management Tool (Outcome Sciences, Inc, Cambridge, MA). Outcome Sciences, Inc serves as the data collection (through their Patient Management Tool) and coordination center for GWTG. The Duke Clinical Research Institute serves as the data analysis center and has institutional board approval to analyze the aggregate deidentified data for research purposes.
Study Population
There were 107 879 patients from 251 fully participating sites in the GWTG-CAD registry between May 1, 2006 and March 21, 2010 that provided the data used for this analysis. Patients were excluded for an admission diagnosis of heart failure with coronary artery disease (N=9706), a non-MI (N=23 696), or an unspecified MI (N=1641). Patients were also excluded for an unknown or unspecified discharge destination (N=484). As a result, there were a total of 72 352 patients enrolled from 237 US sites whose data comprise this analysis.
Variables and Measures
The performance measures in the GWTG-CAD registry have been previously described. 7, 8 The following were included as performance measures at discharge in this analysis: aspirin therapy before hospital admission or within 24 hours, discharge medications, including aspirin, β-blockers, use of ACE inhibitors or ARB agents in patients with left ventricular systolic dysfunction, lipid-lowering therapy for those with low-density lipoprotein >100 mg/dL, and smoking cessation 
WHAT IS KNOWN
• Despite pathophysiologic differences between ST-segment elevation myocardial infarction and non-ST-segment myocardial infarction, the guidelines for medical treatment are nearly identical. • Patients suffering the latter are often afflicted by more numerous medical comorbidity, however, rates of guideline adherence are lower in these patients. • The Get With the Guidelines-Coronary Artery Disease program aims to improve compliance with guideline-based therapy in these patients.
WHAT THE STUDY ADDS
• Rates of guideline adherence are generally high, however, a small difference remains between those suffering ST-segment elevation myocardial infarction and non-ST-segment myocardial infarction. • There may yet be room for improvement in ensuring all patients suffering acute myocardial infarction receive all appropriated guideline-based medical therapy.
counseling in current smokers. A composite of compliance with all performance measures was also included. Quality measures were β-blockers before hospital admission or within 24 hours, discharge medications, including ACE inhibitors or ARB agents, discharge on clopidogrel, lipid-lowering therapy at discharge, rehabilitation or physical activity recommendations, diabetes mellitus treatment and teaching, and physical activity and weight management recommendations for overweight patients. Data evaluating performance and quality measures only included patients without a contraindication or documented intolerance to the specific performance or quality measure and excluded patients who expired, left against medical advice, were discharged to hospice, and those transferred to another facility.
Statistical Analysis
All statistical analyses were performed by the Duke Clinical Research (Durham, NC) using SAS version 9.2 (SAS Institute, Cary, NC). The diagnosis of NSTEMI versus STEMI was the primary independent variable of interest. Percentages and median and interquartile ranges were reported for categorical and continuous variables, respectively. Baseline characteristics were compared using Pearson χ 2 tests for all categorical row variables and χ 2 rank-based group means score statistics for all continuous row variables. Multivariable logistic regression models to determine whether diagnosis of STEMI versus NSTEMI independently influences adherence to performance and quality measures were produced using generalized estimating equations to account for the correlation of data within hospitals. 11 The models adjusted for the potential confounders of age, sex, race (white versus nonwhite), medical history of chronic obstructive pulmonary disease or asthma, diabetes mellitus (combined insulin dependent and noninsulin dependent), hyperlipidemia, hypertension, peripheral vascular disease, stroke or transient ischemic attack, heart failure, renal insufficiency, smoking, geographic region of the United States, teaching hospital, and hospital size represented by number of beds. Age was not imputed because there was no missing data. Sex was not imputed to exclude these observations from the model due to data quality concerns. Hospital characteristics (size, type, and geographic region) were not imputed. Other variables were imputed to values based on missing data patterns. Race was imputed to white. Missingness in medical history variables was imputed to no. All variables included in the models had missing rates of <8%. Odds ratios with their corresponding 95% confidence intervals were reported for each measure. All tests were 2-sided and P values <0.05 were considered statically significant.
Results
Of the 72 352 patients who met the entry criteria for this analysis, there were 23 386 diagnosed with STEMI and 48 966 diagnosed with NSTEMI. The baseline characteristics of the patients are displayed in Table 2 . Individuals suffering NSTEMI were significantly older (median age 69 versus 61 years; P<0.0001) and were more often female (40.2% versus 30.2%; P<0.0001). NSTEMI patients had a higher rate of medical comorbidities compared with STEMI patients. NSTEMI patients had more risk factors and manifestations of vascular disease, as shown by higher rates of hyperlipidemia, prior MI, coronary artery revascularization, prior stroke or transient ischemic attack, peripheral vascular disease, as well as heart failure. Additionally, NSTEMI patients suffered higher rates of morbidity, including diabetes mellitus, kidney disease, chronic obstructive pulmonary disease, and hypertension. Atrial fibrillation and flutter were also more common in NSTEMI patients. However, patients with STEMI were more likely treated at larger hospitals than those with NSTEMI; 35.7% versus 28.4% (P<0.0001) were treated at hospitals with >500 beds. STEMI patients also were more likely to be treated in an academic medical center, 58.0% versus 54.4% (P<0.0001).
The rate of adherence to performance measures was lower in the NSTEMI group compared with STEMI patients for most measures (Table 3) . Compared with NSTEMI patients, STEMI patients had a small but significantly higher compliance rate for the performance measures of receiving aspirin within 24 hours of arrival, or being discharged on aspirin or β-blockers. A more sizeable treatment difference between STEMI and NSTEMI patients was seen in NSTEMI patients with lowdensity lipoprotein >100 mg/dL who received lipid-lowering medications less often (91.0% versus 96.8%; P<0.0001). Of the quality measures, NSTEMI patients received β-blockers within 24 hours of hospital arrival less often, and fewer NSTEMI patients were discharged on ACE inhibitors or ARB agents, aspirin, or clopidogrel. Statin or lipid-lowering medication use was also lower in patients with NSTEMI. In addition, NSTEMI patients received fewer referrals for rehabilitation compared with STEMI patients. The composite of compliance with all applicable performance measures was higher in STEMI patients (94.3% versus 91.1%; P<0.0001).
The odds of patients in the STEMI group receiving guideline-based therapy for which they were eligible were significantly higher than in the NSTEMI group for performance measures of aspirin within 24 hours of arrival, discharge on aspirin, discharge on β-blockers, use of ACE inhibitors or ARB agents for ventricular dysfunction and lipid-lowering medications for those with low-density lipoprotein >100 mg/ dL and the composite of compliance with all of these measures. This also held true for the quality measures, including treatment with β-blockers within 24 hours of arrival, discharge on ACE inhibitors, dual antiplatelet therapy, discharge on statins or lipid-lowering drugs, and physical therapy recommendations. The odds of not receiving diabetes mellitus teaching and weight management recommendations for overweight patients were also higher for NSTEMI patients (Table 4 ). When adjusting for confounding comorbidities, the increase in odds ratios maintained statistical significance for the above measures except for diabetes mellitus treatment and teaching and weight management recommendations (Table 4) .
STEMI patients had a higher adjusted odds of in-hospital mortality than NSTEMI patients (adjusted odds ratio, 1.95; 95% confidence interval, 1.75-2.19). NSTEMI patients were more likely to be transferred to skilled nursing facilities than patients with STEMI, whereas STEMI patients had a higher likelihood of being discharged home than NSTEMI patients. NSTEMI patients were more likely to remain in the hospital for >4 days (Table 5 ).
Discussion
This study, among hospitals participating in GWTG-CAD, compared the use of guideline-recommended medical therapies for patients with NSTEMI and STEMI. With few exceptions, NSTEMI patients were less likely to receive guideline-recommended therapies even after adjusting for demographics, comorbidities, and hospital characteristics. The use of guideline-recommended treatments in eligible patients in this study was higher than previous reported for both STEMI and NSTEMI patients. However, there is a persistent difference in treatment that is concerning as it has been previously demonstrated that use of guideline compliant care is directly associated with survival.
Although differences were observed, for many of the performance measures, the disparity between adherences to guideline-based therapy was small and may be of limited clinical significance. More meaningful was the observation of a treatment gap in the use of lipid-lowering therapy for those with low-density lipoprotein >100 mg/dL. However, the rates of compliance were >90% for both groups across all performance measures. This compares favorably with compliance rates observed with guideline-based therapy from a prior studies from NRMI 4 and OPERA registries collected between 2000 and 2003. 5, 6 This higher rate of guideline adherence in our data, compared with older studies, is encouraging and may suggest that compliance with guideline-based therapy has improved significantly over the past several years across the nation. This improvement may be in part attributable to tools made available to clinicians and hospitals such as the GWTG-CAD program. 12 Because early initiation of medical therapy has been shown to increase long-term compliance in post-MI patients, 13 there is potential for the GWTG-CAD program to have a substantial impact on long-term outcomes. However, further research is required to evaluate the role of programs such as the GWTG to drive improved compliance with evidence-based practice and its translation to improvement in outcomes.
The rates of compliance in quality measures, particularly the use of ACE inhibitors, clopidogrel, and statin therapies for the entire cohort, were lower than compliance with performance measures. The reasons for low rate of use of ACE inhibitors, clopidogrel, and statin therapies require further study. The rates of adherence to guideline-based therapy in our data do, however, compare favorably with long-term treatment rates noted in prior studies involving outpatients with coronary artery disease. 14, 15 Other studies of hospitalized NSTEMI patients have also demonstrated increasing rates of compliance in the past several years, [16] [17] [18] however, a significant proportion of patients who may derive a mortality benefit from such therapies continue to be undertreated. These data can be used to bring additional attention to physicians and hospital personnel that there is underutilization of these medications in MI.
Of note, hospitals treating NSTEMI patients tended to be smaller in size and were less likely to be academic medical centers than centers treating STEMI; therefore, our data, which show that over two thirds of patients received both performance and quality measures of adherence to beneficial therapies, are encouraging. The fact that NSTEMI patients were treated in smaller hospitals may reflect some degree of acute referral bias. STEMI patients may be more likely directed, particularly by the 27% of emergency medical services systems with field electrocardiographic capabilities, 19 to larger hospitals with catheterization laboratory interventional capabilities. This referral bias may have been present in up to a quarter of the STEMI patients in this study. Generally, these hospitals are of greater size and have the financial resources to support continuous catheterization laboratory staffing. Further-more, in many communities, hospitals must maintain certification as STEMI-receiving centers by proving compliance with evidence-based care for STEMI, in particular, a door-toballoon time of <90 minutes. Thus, hospitals treating STEMI may be better situated from a programmatic standpoint and structure to adhere to evidence-based practice than centers without continuous interventional capabilities. In addition, hospitals that participate in a program such as GWTG-CAD may tend to be more organized with regards to performance improvement and guideline-based therapy. This may overestimate the actual compliance rate of guideline-based therapy across the country. Our study was not designed to evaluate such differences. Although our data demonstrated statistically lower compliance for NSTEMI patients, STEMI patients still had higher overall adjusted in-hospital mortality risk. This difference most likely arises from the differing natural history of the disease entities rather than response to guideline-based therapy. Mortality in STEMI is more likely to occur early during the hospitalization, whereas mortality in NSTEMI tends to surpass that of STEMI in the months following initial presentation. 20 This study is limited by lack of longer term follow-up and further research is required to determine whether the disparity in compliance with evidence-based therapy leads to an increase in adverse events or out-ofhospital mortality in NSTEMI patients. Longer term follow-up regarding compliance with medications and lifestyle changes for patients after discharge is also important for achieving durable favorable outcomes after MI.
Some limitations are important to note. The participating centers included in the analysis were voluntarily participating in a national quality improvement program. As such these findings may not apply to patients and hospitals which differ significantly from those participating in GWTG-CAD. All clinical information was abstracted from medical records and depends upon the accuracy of documentation in each hospital, which may not be homogeneous. A proportion of patients reported to be eligible for treatment who did not receive recommended treatments may have had contraindications or intolerance to specific interventions that were present but not documented. Our findings of lower compliance in NSTEMI patients may also be influenced by the greater difficulty in certainty of diagnosis in these patients. There may be residual measured and unmeasured confounding variables which account for some or all of these findings. Because GWTG does not collect data on postdischarge outcomes, the full implications of these differences in performance and quality measure rates for NSTEMI and STEMI patient could not be directly explored.
Conclusions
Contemporary data in a large population of both NSTEMI and STEMI patients treated in diverse hospital settings across the United States indicate a high level of compliance with both performance and quality measures recommended by consensus guidelines. These data demonstrate increased utilization of recommended therapies over historical studies. Differences in compliance are present between NSTEMI and STEMI patients, with STEMI patients meeting guideline standards more consistently. Despite a higher risk from a higher rate of medical comorbidities (or because of them), NSTEMI patients were significantly less likely to receive guideline-recommended medical therapy.
